Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16593142 | 0.82 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL14217283 | 0.82 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL20900404 | 0.82 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL14365721 | 0.81 | MEN1 (0.57) | MEN1KMT2ACASP2DPP7RECQL | |
| SCHEMBL14086890 | 0.80 | KMT2A (0.71) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL23979247 | 0.79 | EPHX1 (0.50) | MEN1KMT2ADPP7GNAI3GNAO1 | |
| SCHEMBL29040294 | 0.78 | MEN1 (0.68) | MEN1KMT2ACASP2RECQLGNAI3 | |
| SCHEMBL15855122 | 0.78 | MEN1 (0.68) | MEN1KMT2ACASP2RECQLGNAI3 | |
| SCHEMBL31035882 | 0.78 | MEN1 (0.68) | MEN1KMT2ACASP2RECQLGNAI3 | |
| SCHEMBL15855121 | 0.78 | MEN1 (0.68) | MEN1KMT2ACASP2RECQLGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | THE J. DAVID GLADSTONE INSTITUTES | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | MAPT, NEFM, PSEN2 | MEN1 4397/4885KMT2A 2108/4885CASP2 2677/4885 |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | MAPT, NEFM, PSEN2 | MEN1 4397/4885KMT2A 2108/4885CASP2 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.